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Case Report
Type 1 Diabetes Mellitus (DM)
Male 22 years of age (Figure 1)




Preparing for surgical treatment
Operation rejected because of:
Blood hypertension (230/110 mmHg)
HBA1C: 10.7 %
Anemia
Renal Insufficiency (not diagnosed)
Hart ischemic changes, left ventricular hypertrophy
(not diagnosed)
DM is a major cause of avoidable blindness all over
the world. Patients with diabetic retinopathy (DR) are
25 times more likely to become blind than non-dia-
betics. Prevalence of type 1 diabetes is 10-15% of the
diabetic population. Prevalence of DR in Wisconsin Epi-
demiological Study of Diabetic Retinopathy was 50.1
and 54.2% in the diabetes control and complications
trial in type 1 diabetes [1] and 35-39% in United King-
dom Prospective Diabetes Study in type 2 diabetes [2].
In two studies from India, the prevalence of DR in type
2 diabetes patients were 34.1% and 37% [3].WHO esti-
mates - India has 31.7 million diabetic subjects at pre-
sent. In USA, DR is the leading cause of new blindness
in people 25-74 years of age. Approximately 700,000
persons have proliferative DR (PDR). Each year another
65,000 are diagnosed with the condition. A recent study
has estimated that among people with diabetes aged 40
or older, 28.5% will develop DR. Worldwide 20 million
people have PDR (very severe eye complication), with
this number projected to increase to over 30 million by
2030. After 10 years of onset of DM, blindness was 1.8,
4.0 and 4.8% in type 1, insulin-treated type 2 and non-
insulin-treated type 2 patients, respectively. In these
three groups of patients, the 10-year incidence visual
impairment (loss of 15 letters on a scale of 0-70 letters)
was 9.4, 37.2 and 23.9%, respectively [4]. Good glycemic
control arrests the development and progression of DR,
but still there are a lot of factors that can influence the
DR visual loss. Technological advances have improved
the diagnostic accuracy of screening methods and given
an access to the diabetic patients to the specialist care.
In the last decades, the treatment strategies have been
revised and besides laser photocoagulation, include sur-
gical interventions and pharmacotherapies. DR will
often go unnoticed when the condition is in its early
stages but advanced symptoms can include blurred or
sudden vision loss. Diabetics are advised to take advan-
tage of the eye screenings which are offered free of
charge in the UK, to detect any signs of the disease.
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Figure 1 Fundus photography of huge retinal bleeding and retinal
detachment in PDR
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Stem cell research, especially the embryonic one, holds
great promise in the search for a cure for type 1 dia-
betes and provide a powerful tool for controlling type 2
diabetes [5]. The first results of the stem-cells DR- treat-
ment were presented at the ARVO in 2011. Patients
experienced improvements in the function of the optic
nerve, blood flow to the eye and reduction of inflamma-
tion in the six-month period following injection and
became stable for the entire follow up period. To
achieve our goals of personalized treatment, we need
EU support in different projects that will connect the
physicians with basic science investigations and biotech-
nology. In the overall economic downturn tremendous
budget cuts will only lead to huge burden of diabetic
complications treatment.
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